Skip to content Skip to sidebar Skip to footer

Tech Stocks

Test text

Against the Odds: What the Gambling Mindset Reveals About Investor Decisions

If you talk to any dedicated pokies player, they’re likely tell you the same thing: they can “feel” when a machine is about to pay out. The same thing is true of day traders. Many will swear they’ve found a pattern in stock charts that’s going to be instrumental in their hitting it big. Both…

ByUjjwal MaheshwariApril 17, 2026

These 8 ASX Growth Stocks Have High P/Es

If you're looking at ASX Growth Stocks with high P/Es you have two choices. First, you could write certain companies off just because of high multiples, only to lose out when such companies continue to grow. Alternatively, you could jump in and risk the company falling and be left red faced - 'If only I'd…

ByNick SundichApril 17, 2026

ASML (NASDAQ:ASML) Q1 sales +15%, but system shipments slowed and stock fell 7%

Net orders beat revenue 1.2x, yet investors punished machine sales ASML (NASDAQ:ASML) sits at the centre of the semiconductor supercycle and remains one of the most important companies in global chip development. Its lithography machines are fundamental to how advanced semiconductors are made, which is why each quarterly result gives investors a useful read on…

ByCharlie YouldenApril 16, 2026

Telix Pharmaceuticals (ASX:TLX) refinances with US$600m 2031 convert at 1.5% coupon

Raises US$600m in convertible debt, cuts refinancing risk ahead of Pixclara PDUFA Telix Pharmaceuticals (ASX:TLX) is sourcing US$600 million of convertible debt, replacing nearer-dated debt with a longer-dated instrument that reduces refinancing pressure and gives the company more room to stay focused on product launches. What stands out to us is the 1.5% coupon. That is…

ByCharlie YouldenApril 15, 2026

IperionX (ASX:IPX) analysts see $9 target, but 2026 is about execution not earnings

GenX scale-up, Titan economics, customer volumes must land Can IperionX (ASX:IPX) really reach the holy grail of titanium manufacturing and emerge as a formidable titanium producer on both the ASX and Nasdaq? Many investors are following the IperionX story, which has ridden a strong wave of momentum after the US push to reshore manufacturing. Titanium remains…

ByCharlie YouldenApril 14, 2026

PainChek (ASX:PCK) lands US$5B Sabra REIT, 20,000 beds worth A$1.5m

What PainChek Just Secured PainChek (ASX:PCK) has entered into a Master Services Agreement with Sabra Health Care REIT, a US$5B Nasdaq-listed healthcare property owner. The deal establishes Sabra as a funded distributor of PainChek across its network of 329 facilities in the US and Canada. The agreement runs for 12 months, with an option to terminate…

ByCharlie YouldenApril 14, 2026

PointsBet (ASX: PBH) is attempting a turnaround and the market is starting to believe it

PointsBet (ASX: PBH) has spent the past two years unwinding one of the more damaging expansion strategies in the ASX small-cap universe. The push into the United States burned capital, eroded confidence and ultimately forced a full strategic reset. That reset is now largely complete. What matters is what happens next. The share price is beginning…

ByCharlie YouldenApril 14, 2026

Here are 5 Recent AI Acquisitions on the ASX! But Are They Just Hype?

This article explores 5 Recent AI Acquisitions on the ASX and whether or not these deals are just 'AI-washing' or have potential to be game-changing. What do we mean by game-changing? Like Pro Medicus' acquisition of Visage was in the GFC - it paid US$3m but has made the company an >A$20bn giant. The AI investment…

ByNick SundichApril 14, 2026

Monash IVF (ASX:MVF) Soul Patts-led bid jumps 12.5% to 90c, final offer

bid lifted to 90c, board must recommend unanimously Monash IVF (ASX:MVF) has announced a revised takeover bid from a consortium of Genesis Capital and WHSP Holdings, increasing the offer from 80c per share to 90c per share, a 12.5% lift. This comes after the board rejected the November proposal. The revised offer remains open until close…

ByCharlie YouldenApril 13, 2026

EML Payments (ASX:EML): The Share Price Is Down Over 90% In 5 years!

EML Payments (ASX:EML) investors who have held shares for the last 5 years have lost 90% of their money and today capped off that long-term decline. In April 2021, the company hit all time highs, but the CBI regulatory shock that came in May of that year changed everything. Since then, the company has promised…

ByNick SundichApril 13, 2026

the Kick-ass Multipurpose WordPress Theme

Tech Stocks

Against the Odds: What the Gambling Mindset Reveals About Investor Decisions

These 8 ASX Growth Stocks Have High P/Es

ASML (NASDAQ:ASML) Q1 sales +15%, but system shipments slowed and stock fell 7%

Telix Pharmaceuticals (ASX:TLX) refinances with US$600m 2031 convert at 1.5% coupon

IperionX (ASX:IPX) analysts see $9 target, but 2026 is about execution not earnings

PainChek (ASX:PCK) lands US$5B Sabra REIT, 20,000 beds worth A$1.5m

PointsBet (ASX: PBH) is attempting a turnaround and the market is starting to believe it

Here are 5 Recent AI Acquisitions on the ASX! But Are They Just Hype?

Monash IVF (ASX:MVF) Soul Patts-led bid jumps 12.5% to 90c, final offer

EML Payments (ASX:EML): The Share Price Is Down Over 90% In 5 years!

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Tech Stocks

Add Your Heading Text Here